TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20236432

Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA) providing ward-based rehabilitation after critical illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA) service delivery model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA) model
Number of subjects: 0
Study: 17074778

Group type: EXPERIMENTAL
Intervention: Swab disinfection with 2-propanol and benzalkonium chloride (SW)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spray disinfection with 2-propanol and benzalkonium chloride (SP)
Number of subjects: 70
Study: 15598453

Group type: EXPERIMENTAL
Intervention: Weight bearing knee flexion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-weight bearing knee flexion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flexion with tibial internal rotation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flexion with tibial external rotation
Number of subjects: 10
Study: 12001325

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) as an adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9787885

Group type: EXPERIMENTAL
Intervention: ECT at 150% above initial seizure threshold
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-dose ECT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ECT (both types)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Acute surge in oxytocin levels at the ninth ECT
Number of subjects: 55
Study: 7897158

Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg, by mouth, daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 7
Study: 2698894

Group type: EXPERIMENTAL
Intervention: Lidocaine periodontal ligament injections
Number of subjects: 28

Group type: COMPARATOR
Intervention: Epinephrine periodontal ligament injections
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 28
Study: 4802389

Group type: EXPERIMENTAL
Intervention: 1000 CCA unit Aichi/68 influenza vaccine
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: 1000 CCA unit Japan/57 influenza vaccine
Number of subjects: 687
Study: 31586833

Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Mental Health Literacy (MHL) conducted by clinicians
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Mental Health Literacy (MHL) conducted by dis-peer instructors
Number of subjects: 221
Study: 27449500

Group type: EXPERIMENTAL
Intervention: Adjunctive peri-operative steroid combination (triamcinolone acetonide) 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml into the sub-Tenon's space.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard surgical treatment and routine pre-operative and post-operative treatment and care.
Number of subjects: 300
Study: 24789702

Group type: EXPERIMENTAL
Intervention: Family-centered nursing care (including physical, psychological, and social interventions)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 240
Study: 23405790

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20547795

Group type: EXPERIMENTAL
Intervention: Fixed-dose artesunate-mefloquine (AS-MQ) - 100 mg AS and 200 mg MQ/tablet daily for 3 days (days 0, 1, and 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonfixed artesunate plus mefloquine (AS-plus-MQ) - 4 mg/kg AS/day for 3 days plus 15 mg/kg MQ on day 1 and 10 mg/kg on day 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fixed-dose AS-MQ
Number of subjects: 50
Study: 18543307

Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR > 75.0 mL/min/1.73 m² (Group I)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR 60.0 to 74.9 mL/min/1.73 m² (Group II)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR 45.0 to 59.9 mL/min/1.73 m² (Group III)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR ≤ 45.0 mL/min/1.73 m² (Group IV)
Number of subjects: 346
Study: 15878723

Group type: EXPERIMENTAL
Intervention: Chronic treatment with haloperidol (3‐10 mg/day for 2‐4 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (Normal participants with no experience with antipsychotic drugs)
Number of subjects: 10
Study: 12902363

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention for Trauma in Schools (10-session standardized cognitive-behavioral therapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Wait-list delayed intervention (control group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Both groups received the intervention (after 6 months)
Number of subjects: 126
Study: 9581986

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (Ome20)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (Ome10)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (Ome20) in oesophagitis patients
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (Ome10) in oesophagitis patients
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up (6 months off treatment)
Number of subjects: 538
Study: 1832753

Group type: EXPERIMENTAL
Intervention: Inpatient treatment group
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Outpatient treatment group
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 459
Study: 6810013

Group type: EXPERIMENTAL
Intervention: Sustak 6.4 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31545099

Group type: EXPERIMENTAL
Intervention: Winning (n = 110)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Break-even (n = 103)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Losing (n = 105)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Impulsivity (negative and positive urgency)
Number of subjects: 318
Study: 28635153

Group type: EXPERIMENTAL
Intervention: Silymarin gel 1% applied twice daily for 9 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26890474

Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 106

Group type: COMPARATOR
Intervention: No drain placement (control)
Number of subjects: 106
Study: 24188499

Group type: EXPERIMENTAL
Intervention: pBFR (practical blood flow restriction) for elbow flexors during the first 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HI-BFR (high-intensity resistance training with blood flow restriction) during the second 4 weeks
Number of subjects: 20
Study: 20947374

Group type: EXPERIMENTAL
Intervention: Vorapaxar (1 or 2.5 mg) plus aspirin (75-150 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo plus aspirin (75-150 mg/day)
Number of subjects: 90
Study: 20634633

Group type: EXPERIMENTAL
Intervention: Nei-Guan acupressure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Finger acupressure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Relief band
Number of subjects: 51
Study: 17568349

Group type: EXPERIMENTAL
Intervention: Epi-LASIK
Number of subjects: 29
Study: 15316750

Group type: EXPERIMENTAL
Intervention: 100 mg oral docetaxel combined with 500 mg OC144‐093
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg i.v. docetaxel
Number of subjects: 12
Study: 11172188

Group type: EXPERIMENTAL
Intervention: Discontinuation of therapy for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuation of therapy
Number of subjects: 16
Study: 9641004

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 12
Study: 7586104

Group type: EXPERIMENTAL
Intervention: Maintaining temperature at 34 degrees C without rewarming
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rewarming to 36-37 degrees C
Number of subjects: 30
Study: 2138182

Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg single injection, continuous infusion at 5 and 10 micrograms/kg.min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 6777804

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study: 31183369

Group type: EXPERIMENTAL
Intervention: Dual locking plates in orthogonal configuration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dual locking plates in adjacent configuration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dual locking plates
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dual locking plates (adjacent and orthogonal) after removal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional dual plates
Number of subjects: 32
Study: 27916746

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1811
Study: 27701064

Group type: COMPARATOR
Intervention: SMART Recovery (SR) meetings alone
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Overcoming Addictions (OA) and SMART Recovery (OA+SR)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Both SR and OA
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Participants who stopped drinking before joining the trial
Number of subjects: 189
Study: 23769325

Group type: EXPERIMENTAL
Intervention: Improved adherence to medication
Number of subjects: 363
Study: 22993335

Group type: EXPERIMENTAL
Intervention: PEG-interferon α-2b (PEG-IFN) for up to 5 years
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Observation-alone
Number of subjects: 1256
Study: 19543808

Group type: EXPERIMENTAL
Intervention: Heteroscedasticity-adjusted OLS (full model)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CLAD (short model)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CLAD (reduced model)
Number of subjects: 151
Study: 17522936

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic restorative proctocolectomy (LRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open restorative proctocolectomy (ORP)
Number of subjects: 60
Study: 15791380

Group type: EXPERIMENTAL
Intervention: Psychomotor training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no psychomotor training)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Residents (group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medical students (group 3)
Number of subjects: 48
Study: 11433751

Group type: EXPERIMENTAL
Intervention: 2-hour instillation of pirarubicin (THP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 5-min instillation of pirarubicin (THP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 79
Study: 9885751

Group type: EXPERIMENTAL
Intervention: Argon laser punctal ablation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Electrocautery punctal occlusion
Number of subjects: 32
Study: 8058420

Group type: EXPERIMENTAL
Intervention: Albuterol administered by metered dose inhaler through a spacer device (Babyhaler)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2221865

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) taken 1 hour before a meal (BE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) taken with a meal (WI)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) taken 1 hour after a meal (AF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 250 ml
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 450 ml
Number of subjects: 28
Study: 657082

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (30 mg/kg total dose) given for one six-day course immediately after mastectomy
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (30 mg/kg total dose)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (30 mg/kg total dose) given 3 weeks after mastectomy
Number of subjects: 507
Study: 31791707

Group type: EXPERIMENTAL
Intervention: Positive emotional writing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-emotive control writing task
Number of subjects: 72
Study: 31424709

Group type: EXPERIMENTAL
Intervention: HBP-Foam (0.05%)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 560
Study: 28207554

Group type: EXPERIMENTAL
Intervention: Isolated troponin rise (ITR)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome (ACS)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 312
Study: 25621553

Group type: EXPERIMENTAL
Intervention: Tuber‐Plant
Number of subjects: 97

Group type: COMPARATOR
Intervention: Bio‐Plant
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 97
Study: 23945188

Group type: EXPERIMENTAL
Intervention: Vietnamese RUTF (locally developed bar)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Plumpy'nut® (commercially available peanut-based RUTF paste)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both RUTFs (Vietnamese RUTF and Plumpy'nut®)
Number of subjects: 67
Study: 21305590

Group type: EXPERIMENTAL
Intervention: Staggered furosemide and desmopressin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 19826132

Group type: EXPERIMENTAL
Intervention: Daunorubicin
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 2157
Study: 17086503

Group type: EXPERIMENTAL
Intervention: Workplace intervention (workplace assessment, work modifications, and case management)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical intervention (physiotherapy based on operant behavioural principles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workplace intervention followed by clinical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (provided by an occupational physician)
Number of subjects: 0
Study: 15483784

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (6 g ethyl ester daily for 16 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Safflower oil (SO) supplementation (6 g ethyl ester daily for 16 weeks)
Number of subjects: 22
Study: 11686813

Group type: COMPARATOR
Intervention: Manual toothbrush (Crest Complete)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Powered toothbrush (Braun 3D Plaque Remover)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (Manual and Powered toothbrush)
Number of subjects: 47
Study: 9623428

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (pancuronium or gallamine)
Number of subjects: 13
Study: 7888537

Group type: EXPERIMENTAL
Intervention: Didanosine (buffered powder for oral solution, total daily doses of 6.6‐10 mg/kg)
Number of subjects: 21198
Study: 3184196

Group type: COMPARATOR
Intervention: CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone) alone for 6 monthly cycles
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: CVPP plus RT (radiation therapy, 3,000 rad)
Number of subjects: 277

Group type: COMPARATOR
Intervention: CVPP alone
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: CVPP plus RT
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: RT plus CVPP
Number of subjects: 277
Study: 4880663

Group type: EXPERIMENTAL
Intervention: 1.0 g of tetracycline, divided into 4 doses, daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 g of tetracycline in a single dose daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of 1.0 g of tetracycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multivitamin preparations
Number of subjects: 0
Study: 31755823

Group type: EXPERIMENTAL
Intervention: RABB (210 kcal)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SSM (210 kcal)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MCM (635 kcal)
Number of subjects: 21

Group type: COMPARATOR
Intervention: NF (0 kcal)
Number of subjects: 21
Study: 31200019

Group type: EXPERIMENTAL
Intervention: Streptavidin affinity grids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sample preparation methods
Number of subjects: 0
Study: 28595249

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesives
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 71
Study: 25950180

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal glucose tolerance group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Whole population studied
Number of subjects: 41
Study: 23587397

Group type: EXPERIMENTAL
Intervention: PF stents
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: BD stents
Number of subjects: 989

Group type: COMPARATOR
Intervention: PP stents
Number of subjects: 989
Study: 21972615

Group type: EXPERIMENTAL
Intervention: Moxibustion at Guanyuan (CV 4) and Shenque (CV 8) in addition to standard treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group treatment including Mifepristone, Rivanol, Misoprostol, uterine curettage, and Oxytocin
Number of subjects: 100
Study: 19226886

Group type: EXPERIMENTAL
Intervention: Learning needs identified among first-time CABG patients
Number of subjects: 0
Study: 16738738

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day of zinc sulfate for four months)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 58
Study: 15327560

Group type: EXPERIMENTAL
Intervention: TriAc (0.1% in hydrophilic ointment) applied twice daily for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TriAc
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11241460

Group type: COMPARATOR
Intervention: 15 microg and placebo
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: 15 microg and 15 microg booster
Number of subjects: 815

Group type: COMPARATOR
Intervention: 30 microg and placebo
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: 30 microg and 15 microg booster
Number of subjects: 815
Study: 9285265

Group type: EXPERIMENTAL
Intervention: Suppressing the thought of weighing themselves
Number of subjects: 40

Group type: COMPARATOR
Intervention: Expressing the thought of weighing themselves
Number of subjects: 40
Study: 8275621

Group type: EXPERIMENTAL
Intervention: 10 mg candoxatril
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50 mg candoxatril
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 200 mg candoxatril
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3755916

Group type: EXPERIMENTAL
Intervention: Vestibular stimulation (10 infants)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (7 infants)
Number of subjects: 17
Study: 30218372

Group type: EXPERIMENTAL
Intervention: Religious intervention using Tavasol prayer and four recommended remembrances in 7 sessions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 28681988

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg/d
Number of subjects: 72
Study: 26934454

Group type: COMPARATOR
Intervention: Biologics
Number of subjects: 1047

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 1047
Study: 25336939

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing intervention with upper body resistance training (SE-UBR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Health education with upper body resistance training (ED-UBR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Health education with gentle chair exercises (ED-Chair)
Number of subjects: 49
Study: 21225314

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin plus 7.5 mg/m² rh-endostatin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin alone
Number of subjects: 66
Study: 20546822

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (M-M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond primer and Phenyl-P in bonding (M-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenyl-P in primer and Clearfil SE Bond bonding (P-M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenyl-P in primer and bonding (P-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All adhesive systems containing MDP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 18795912

Group type: EXPERIMENTAL
Intervention: Lean body mass (LBM)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Total body bone mineral content (TBMC)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Total bone mineral density (TBMD)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Body weight, height, total energy expenditure (TEE), physical activity level (PAL), father's educational level, and gender at age 15
Number of subjects: 203
Study: 16248237

Group type: EXPERIMENTAL
Intervention: Shensong yangxin capsule (SYC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Xinlvning tablet (Control)
Number of subjects: 221